Ih2 Inhibition Enhances Proteasome Inhibitor Responsiveness in Hematological Malignancies

Hematological Oncology - United Kingdom
doi 10.1002/hon.200_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Next-Generation XPO1 Inhibitor Shows Improved Efficacy and in Vivo Tolerability in Hematological Malignancies

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2016English

Telomerase Activation in Hematological Malignancies

Genes
Genetics
2016English

Bridging the Gap in Hematological Malignancies

Expert Review of Hematology
Hematology
2012English

Phase 1 Study of Ixazomib, an Investigational Proteasome Inhibitor, in Advanced Non-Hematologic Malignancies

Investigational New Drugs
OncologyPharmacology
2015English

I(5)(p10) in Hematological Malignancies

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2019English

Advances in Immunotherapy for Hematological Malignancies

Journal of Nihon University Medical Association
2016English

Aspergillosis With Hematological Malignancies in Our Facility

International Journal of Infectious Diseases
MedicineInfectious DiseasesMicrobiology
2019English

Mechanism of Action of Lenalidomide in Hematological Malignancies

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2009English

Molecular Cytogenetics of Childhood Hematological Malignancies

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
1997English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy